BioMarin Pharmaceutical Inc. $BMRN Position Boosted by Eleva Capital SAS

Eleva Capital SAS lifted its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 33.8% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 31,339 shares of the biotechnology company’s stock after acquiring an additional 7,920 shares during the quarter. BioMarin Pharmaceutical makes up 0.4% of Eleva Capital SAS’s portfolio, making the stock its 10th biggest position. Eleva Capital SAS’s holdings in BioMarin Pharmaceutical were worth $1,697,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Dodge & Cox increased its position in BioMarin Pharmaceutical by 1.0% during the 2nd quarter. Dodge & Cox now owns 15,108,310 shares of the biotechnology company’s stock valued at $830,504,000 after purchasing an additional 153,070 shares during the period. Viking Global Investors LP boosted its stake in shares of BioMarin Pharmaceutical by 13.8% during the 2nd quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company’s stock valued at $675,505,000 after purchasing an additional 1,488,552 shares in the last quarter. AQR Capital Management LLC boosted its stake in shares of BioMarin Pharmaceutical by 90.7% during the 2nd quarter. AQR Capital Management LLC now owns 5,580,573 shares of the biotechnology company’s stock valued at $306,429,000 after purchasing an additional 2,654,768 shares in the last quarter. Geode Capital Management LLC increased its position in shares of BioMarin Pharmaceutical by 1.3% during the second quarter. Geode Capital Management LLC now owns 3,474,438 shares of the biotechnology company’s stock valued at $190,417,000 after buying an additional 43,185 shares during the period. Finally, Norges Bank bought a new position in BioMarin Pharmaceutical in the second quarter worth about $112,352,000. Hedge funds and other institutional investors own 98.71% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $66.00 price objective on shares of BioMarin Pharmaceutical in a research report on Tuesday, October 28th. Barclays started coverage on BioMarin Pharmaceutical in a research report on Wednesday, January 28th. They set an “overweight” rating and a $80.00 price target on the stock. Wells Fargo & Company increased their price objective on BioMarin Pharmaceutical from $70.00 to $75.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Stifel Nicolaus restated a “hold” rating and set a $61.00 target price (down previously from $73.00) on shares of BioMarin Pharmaceutical in a report on Thursday, November 6th. Finally, Leerink Partners downgraded shares of BioMarin Pharmaceutical from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $82.00 to $60.00 in a research report on Wednesday, December 3rd. Fifteen investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $88.14.

BioMarin Pharmaceutical Price Performance

Shares of NASDAQ:BMRN opened at $64.08 on Monday. BioMarin Pharmaceutical Inc. has a 1-year low of $50.76 and a 1-year high of $73.51. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.83 and a quick ratio of 3.10. The business has a fifty day moving average price of $58.09 and a 200-day moving average price of $56.02. The company has a market capitalization of $12.31 billion, a PE ratio of 24.09, a PEG ratio of 0.70 and a beta of 0.26.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.